Click to cancel search
Login
Sign Up
Home Page
How It Works
Our Story
Symptom Checker
Second Opinion Finder
Newsroom
Partner With Us
MediFind Pro
FAQ
Are we missing a condition or feature you’d like to see? MediFind is always evolving and we’d love your feedback.
Submit Feedback
Advertising Policy
Privacy Policy
Terms & Conditions
Condition
Condition
Doctor
Symptom
Condition
Click to search for condition or expert
Login
Sign Up
Click to open main menu
Share
Share
Share
Click
Share
Share
Condition
Acute Myelomonocytic Leukemia
Symptoms, Doctors, Treatments, Research & More
Overview
Find a Doctor
Latest Research
Clinical Trials
Condition 101
What are the alternative names for Acute Myelomonocytic Leukemia?
AML-M4
Acute myeloblastic leukemia type 4
AML M4
AMMoL
Top Global Doctors
Click to see doctor options
NV
Elite
Norbert Vey
Marseille, 93, FR
Click to see doctor options
CD
Elite
Courtney D. Dinardo
Hematology
Oncology
Internal Medicine
Houston, TX
Click to see doctor options
RW
Elite
Roland B. Walter
Hematology
Oncology
Internal Medicine
Seattle, WA
Click to see doctor options
CP
Elite
Claude Preudhomme
Lille, 32, FR
Click to see doctor options
MP
Elite
Mrinal M. Patnaik
Hematology
Internal Medicine
Rochester, MN
Click to see doctor options
EJ
Elite
Elias J. Jabbour
Hematology
Oncology
Internal Medicine
Houston, TX
Latest Research
Latest Advance
Study
Condition:
Acute Myeloid Leukemia
Journal:
The Lancet. Haematology
Treatment Used:
10-day Decitabine with Venetoclax
Number of Patients:
168
Published —
September 08, 2020
The study researched the safety and effectiveness of 10-day decitabine with venetoclax for acute myeloid leukemia.
Latest Advance
Study
Condition:
Myelodysplastic Syndromes and Acute Myeloid Leukemia
Journal:
Leukemia research
Treatment Used:
Azacitidine
Number of Patients:
18
Published —
May 23, 2020
In this study, researchers evaluated the safety and effectiveness of azacitidine for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Clinical Trials
Clinical Trial
Drug
Status:
Not yet recruiting
Study Type:
Drug
Participants:
72
Start Date:
December 21, 2020
A Phase 1 Study of MLN7243 (TAK-243) for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents
Clinical Trial
Drug
Status:
Not yet recruiting
Study Type:
Drug
Participants:
240
Start Date:
December 1, 2020
A Randomized Phase II Study to Compare ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
